quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:44:35·185d
ANALYSTRating
Bolt Biotherapeutics Inc. logo

H.C. Wainwright resumed coverage on Bolt Biotherapeutics with a new price target

BOLT· Bolt Biotherapeutics Inc.
Health Care
Original source

Companies

  • BOLT
    Bolt Biotherapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 20UpdateH.C. Wainwright$7.00
  • Jan 6UpdateMorgan Stanley$11.00
  • Jan 6UpdateMorgan Stanley-
  • Nov 10UpdateSVB Leerink$33.00
  • Aug 16UpdateSVB Leerink$35.00

Related

  • SEC42d
    SEC Form S-8 filed by Bolt Biotherapeutics Inc.
  • SEC42d
    SEC Form 10-K filed by Bolt Biotherapeutics Inc.
  • SEC42d
    Bolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR42d
    Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
  • PR58d
    Bolt Biotherapeutics to Participate in Upcoming March Conferences
  • INSIDER78d
    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)
  • INSIDER78d
    SEC Form 4 filed by Chief Operating Officer Yonehiro Grant
  • INSIDER78d
    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022